The company’s vaccine platform enables multiple development tracks to be pursued simultaneously. The priority programmes in influenza and pneumococcal disease are both in critical phases, while additional development projects create future opportunities to broaden the pipeline.

Emma Ispasanie – Translational Project Scientist

As part of this development, Abera welcomes PhD Emma Ispasanie, who takes up the role of Translational Project Scientist. Emma Ispasanie is an immunologist with solid experience in OMV-based technologies and vaccine development in the preclinical to early clinical phase, where several of Abera’s projects are currently positioned. She has completed postdoctoral studies in immunology and has international experience from research and development environments with a focus on translational vaccine development.

In her role, she will work to drive the company’s pipeline projects forward towards and through clinical phase 1, with a particular focus on translational development, project execution, and the interface between preclinical data and clinical planning.

“We are at a stage where both speed and quality are critical. Emma has a very strong and highly relevant profile, and her expertise in immunology, OMVs and clinical preparation is an important addition as we now advance several key projects in parallel,” says Maria Alriksson, CEO of Abera Bioscience.